Patent · US Active

GPR119 agonists

US11512065B2 · kind B2 · utility

3Cited by

4References

20Claims

0Family size

Assignee

KALLYOPE, INC. · US

Inventors

Iyassu Sebhat · Jersey City, US
Shuwen He · Fanwood, US
Christopher Moyes · Westfield, US

Key dates

Filing date	Feb 3, 2022
Grant date	Nov 29, 2022
Priority date	—
Expiry date	Feb 3, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H15/26
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.